Lumida
/NTLA
⌘K
Intellia Therapeutics Inc

Intellia Therapeutics Inc

NTLA
$11.74USD-1.59%-0.19 today

MARKET CAP

1.6B

P/E (TTM)

FWD P/E

DAY RANGE

$12 – $12

52W RANGE

$8
$28

AI Summary

Stalk
Sell NowMedium

NTLA remains entrenched in a pronounced downtrend, with price trading well below its major moving averages and having broken key support. Stage 4 distribution and bearish EMA alignment confirm medium-term skew to the downside, while short-term weakness and failed rallies into the 9/20 EMA and 50 SMA zones align timing for immediate downside participation. Execution is recommended now on any bounce toward those resistance areas for rejection and continuation.

  • Lombosi Phase 3 data showed an 87% reduction in mean monthly attacks, with 62% of patients attack-free
  • Intellia held $628.4M cash as of Q2 2026, supporting R&D into at least 2028
  • Q2 2026 net loss was $106.6M, up from $101.3M year-over-year
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$33.1M$52.1M$36.3M$57.9M$67.7M
YoY %-43.0%+57.7%-30.4%+59.6%+16.9%
P / Sales253.6x51.2x75.4x19.9x14.4x
EV / Sales257.6x46.6x76.1x22.2x14.6x
Gross Profit, Adj.$33.1M$52.1M$36.3M$57.9M$67.7M
YoY %-43.0%+57.7%-30.4%+59.6%+16.9%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit257.6x46.6x76.1x22.2x14.6x
EBITDA, Adj.$-261.0M$-450.6M$-506.3M$-524.0M$-431.2M
YoY %-100.3%-72.7%-12.4%-3.5%+17.7%
Margin %-789.5%-864.5%-1395.8%-905.3%-637.2%
EV / EBITDA-32.6x-5.4x-5.5x-2.4x-2.3x
EBIT$-267.9M$-471.6M$-515.3M$-534.3M$-441.0M
YoY %-96.1%-76.1%-9.3%-3.7%+17.5%
Margin %-810.4%-904.9%-1420.5%-923.1%-651.7%
EV / EBIT-31.8x-5.1x-5.4x-2.4x-2.2x
Net Income$-267.9M$-474.2M$-481.2M$-519.0M$-412.7M
YoY %-99.6%-77.0%-1.5%-7.9%+20.5%
Net Margin-810.5%-909.8%-1326.5%-896.8%-609.9%
EPS (GAAP)-$3.78-$6.16-$5.42-$5.25-$3.81
YoY %-57.5%-63.0%+12.0%+3.1%+27.4%